DECRYPTION – An injectable molecule opens very promising perspectives for the management of the disease.
These are data that were eagerly awaited. Published in the New England Journal of Medicine on July 21, they are by far the hopes of obesity specialists, and it is for patients, perhaps, the beginning of a new era in their care.
The Surmont-1 phase 3 clinical trial evaluated the efficacy of tirzépide, an injectable treatment developed by the Eli Lilly laboratory. Patients who received a weekly dose of 10 or 15 mg of tirzepatide had lost an average of 20% of their weight after 72 weeks. This may seem limited, but the impact on their state of health is very significant. “About a third of these patients even exceed the 25% weight loss mark, unheard of with obesity drugs», enthuses Dr. Lucie Favre, executive doctor in the endocrinology and diabetology department and released from the Center hospitalo-universitaire vaudois, in Lausanne (Switzerland). Indeed, to date only surgery…